CJC-1295 (no DAC) + Ipamorelin
A pre-mixed vial of two lab-made peptides: CJC-1295 without DAC (Mod GRF 1-29), a growth hormone–releasing hormone analogue, and ipamorelin, which acts on the ghrelin receptor. Both make the pituitary release growth hormone, through two different receptors. The pairing is popular online, but no study has tested the combination.
Approval status
Neither component is an approved medicine. In 2024 FDA's compounding advisers voted against adding either one to the list of substances pharmacies may compound from.12345
What it’s used or studied for
There are no published studies of this combination itself. See the page for each part.
Each label shows how strong the evidence is: an approved use, human studies, animal or lab studies only, or a popular claim with no published studies. Being studied is not the same as being proven safe or effective.
Side effects
No study has tested this blend; FDA found no human studies of CJC-1295 without DAC at all. The side effects are those of each component.4
A blend carries the side effects and cautions of each of its parts.
Cautions
- A 2026 clinical review says the case for combining them rests mainly on anecdote, with limited controlled evidence of any added benefit.6
Sources
- FDA: Final summary minutes, Pharmacy Compounding Advisory Committee, December 4, 2024 (CJC-1295)
- FDA: Final summary minutes, Pharmacy Compounding Advisory Committee, October 29, 2024 (ipamorelin)
- WADA 2026 Prohibited List
- FDA briefing document: CJC-1295-related bulk drug substances (Pharmacy Compounding Advisory Committee, December 4, 2024)
- FDA briefing document: Ipamorelin acetate and ipamorelin (Pharmacy Compounding Advisory Committee, October 29, 2024)
- Dominikowski A et al. Performance-enhancing peptides modulating the GH-IGF1 axis: clinical evidence vs self-administration (Front Endocrinol, 2026)
Spotted a mistake on this page? Report it. The email opens with the peptide and vial already filled in.